Paper Details

Paper Title

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.

Paper Journal Title

Br J Cancer

Paper Citation Count

Paper Publication Year

2012

Bio Mention

Mesh Descriptor

Paper Details

Column Actions

Datasets